A Phase 3 interventional study of NOVA22007 (Ciclosporin 0.1%) and NOVA22007 in Moderate to Severe Dry Eye Syndrome, sponsored by Santen SAS. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-16.
Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing cyclosporine in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. Cyclosporine · Lymphoma, Follicular.
Among the 20 studies testing cyclosporine in Lymphoma, Follicular, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2007, is one of 3 in phase 3, and was the 19th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →None of the 20 studies testing cyclosporine in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →
Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 3
First in 1996; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 482 is above the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 20 across the 19 interventional studies. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Santen SAS, one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen SAS is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
Santen Pharmaceutical Co., Ltd. has 1 study filed under Lymphoma, Follicular — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing cyclosporine in Lymphoma, Follicular, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ciclosporin 0.1%
Drug: NOVA22007 (Ciclosporin 0.1%)
Vehicle
Drug: NOVA22007
Ciclosporin 0.1% Ophthalmic Emulsions
Vehicle
Corneal fluorescein staining (on modified Oxford scale)
Time frame: Approximately 26 weeks
Patient's global score of all symptoms of ocular discomfort unrelated to study medication instillation, using a visual analog scale (VAS) ranging from 0%-100%
Time frame: Approximately 26 weeks
• Ocular Symptom Disease Index© (OSDI©) questionnaire • Percentage of complete responder to corneal fluorescein staining (on modified Oxford scale), i.e. with corneal staining score =0 • Patient's score of each symptom of ocular discomfort unrelated to
Time frame: Approximately 26 weeks
The record gives a start of Sep 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine